Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel SERD, LSZ102, shows promise for pretreated ER+ breast cancer

Key clinical point: The oral SERD LSZ102 plus ribociclib or alpelisib shows manageable safety and encouraging clinical activity for heavily pretreated ER+ breast cancer.

Major finding: The ORRs ranged from 1.3% to 15.8% across arms, and PFS ranged from 1.8 to 6.2 months.

Study details: A phase 1/1b study of 193 patients.

Disclosures: This study was funded by Novartis. Dr. Jhaveri reported advisory and consultancy roles and/or research grants or other funding to her institution from Novartis, ADC Therapeutics, Pfizer, and numerous other pharmaceutical and biotechnology companies. Dr. Cinieri reported relationships with Lily Oncology, Pfizer, Roche, AstraZeneca, Amgen, Novartis, including honoraria, grant and research support to his institution, advisory board participation, and scientific meeting support.

Citation:

Jhaveri K et al. ESMO Breast Cancer, Abstract LBA1.